CTXR - キティウス・ファ―マシュ―ティカルズ (Citius Pharmaceuticals Inc.) キティウス・ファ―マシュ―ティカルズ

 CTXRのチャート


 CTXRの企業情報

symbol CTXR
会社名 Citius Pharmaceuticals Inc (キティウス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Citius Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products adjunctive cancer care and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30 2016 the Company had not generate any revenues.   キティウス・ファ―マシュ―ティカルズは米国の特殊医薬品メ―カ―。抗感染症薬、がん補助療法、処方薬に焦点を置いた治療薬の開発や商品化に従事する。開発中の薬剤には、カテ―テル関連血流感染を対象とした抗菌薬ロックソリュ―ション「Mino-Lok」や、痔核治療での炎症や麻酔痛を軽減するヒドロコルチゾン-リドカイン局所製剤がある。本社所在地はニュ―ジャ―ジ―州。   Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
本社所在地 11 Commerce Drive First Floor Cranford NJ 07016 USA
代表者氏名 Leonard L. Mazur Leonard L. Mazur
代表者役職名 Executive Chairman of the Board Secretary
電話番号 +1 908-967-6677
設立年月日 40422
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url www.citiuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/ctxr
adr_tso
EBITDA EBITDA(百万ドル) -12.52810
終値(lastsale) 1.7899
時価総額(marketcap) 28994216.0109
時価総額 時価総額(百万ドル) 27.69993
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 25.11109
当期純利益 当期純利益(百万ドル) -12.73298
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Citius Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $9.7M. Higher net loss reflects Research and Development increase of 96% to $4.8M (expense) General and administrative increase of 8% to $4.7M (expense) Gain/Loss on Derivatives - Hedging decrease from $309K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.48 to -$1.01.

 CTXRのテクニカル分析


 CTXRのニュース

   Citius Pharmaceuticals Inc Shares Close the Week 24.7% Higher - Weekly Wrap  2021/04/30 22:30:00 Kwhen Finance
Citius Pharmaceuticals Inc (CTXR) shares closed this week 24.7% higher than it did at the end of last week. The stock is currently up 132.4% year-to-date, up 172.4% over the past 12 months, and down 23.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $2.52 and as low as $1.87 this week.Trading volume this week was 16.9% higher than the 10-day average and 102.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 189.3% The company's stock price performance over the past 12 months beats the peer average by 80.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Citius Pharmaceuticals Inc Shares Close the Week 51.5% Higher - Weekly Wrap  2021/02/19 22:30:00 Kwhen Finance
Citius Pharmaceuticals Inc shares closed this week 51.5% higher than it did at the end of last week. The stock is currently up 102.0% year-to-date, up 146.1% over the past 12 months, and down 33.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.7%. Trading Activity Shares traded as high as $2.16 and as low as $1.30 this week.Shares closed 5% below its 52-week high and 4e+2% above its 52-week low.Trading volume this week was 42.3% lower than the 10-day average and 79.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 17.3% The company's stock price performance over the past 12 months beats the peer average by 23.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Citius Pharmaceuticals Inc Shares Close the Day 32.1% Higher - Daily Wrap  2021/02/19 22:30:00 Kwhen Finance
Citius Pharmaceuticals Inc shares closed today 32.1% higher than it did at the end of yesterday. The stock is currently up 102.0% year-to-date, up 146.1% over the past 12 months, and down 33.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $2.16 and as low as $1.30 this week.Shares closed 5% below its 52-week high and 4e+2% above its 52-week low.Trading volume this week was 42.3% lower than the 10-day average and 79.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 17.3% The company's stock price performance over the past 12 months beats the peer average by 23.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Citius Pharmaceuticals set to join Russell 2000 Index  2021/06/07 14:20:07 Seeking Alpha
   Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19  2021/04/19 12:53:14 Benzinga
The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies like Pfizer, Inc. ( NYSE: PFE ) , Syndax Pharmaceuticals ( NASDAQ: SNDX ), Merck & Co. ( NYSE: MRK ), and Amgen, Inc. (NASDAQ: AMGN ), among others, understand the importance of creating new, effective pharmaceutical critical care products for unmet needs. For example, long-term patients with central venous catheters (CVCs) for dialysis or cancer treatments are still at risk for complications related to bloodstream infections that might be fatal. This creates a new set of needs in order to have successful outcomes for these patients. Finding ways to avoid these complications can be lifesavers. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ), a specialty pharmaceutical company dedicated to developing and commercializing novel critical care drug products, is addressing several of these unmet medical needs with cost-saving and cost-effective solutions with low-risk development pathways.
   Thinking about buying stock in Nio, Norwegian Cruise Line, Immunovant, Devon Energy, or Citius Pharmaceuticals?  2021/03/08 15:55:00 PR Newswire
NEW YORK, March 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, NCLH, IMVT, DVN, and CTXR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?  2021/02/18 15:55:00 PR Newswire
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field  2021/02/04 15:16:13 Benzinga
Citius Pharmaceuticals, Inc. was one of the sponsors for the Benzinga Global Small-Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Despite current medical advances, there are still many medical conditions with unmet needs. For example, long-term patients with Central Venous Catheters (CVCs) for dialysis or cancer treatment are still at risk for complications related to bloodstream infections that might be fatal. Complications associated with CVC placement can present a 12%-25% morbidity and mortality, resulting in burdening hospitals and healthcare institutions with costs, hospital days, and patient quality of life. Thus, management and prevention should be the ultimate goal for positive treatment outcomes. A company that understands the importance of unmet needs is Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ).

 関連キーワード  (医薬品 米国株 キティウス・ファ―マシュ―ティカルズ CTXR Citius Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)